Aclaris Therapeutics, Inc. (ACRS)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1557746 · fiscal year ends in Dec
Closing price $4.00 on 29 Oct 2026; 52-week range $2.13 to $6.54.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $8.2M
- Revenue growth
- -51.0%
- Net income, last twelve months
- -$75.7M
- Earnings per share
- -$0.58
- Gross margin
- 79.5%
- Operating margin
- -1050.2%
- Net margin
- -921.5%
- Free cash flow
- -$62.2M
- Return on equity
- -60.8%
- Market value
- $559.3M
- Cash
- $19.2M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 139.8M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $7.8M | -$76.4M | -$64.9M | -$0.53 | -$47.2M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $18.7M | -$141.9M | -$132.1M | -$1.71 | -$20.2M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $31.2M | -$97.4M | -$88.5M | -$1.27 | -$79.6M | 10-K filed 27 Feb 2024 |
| FY2022 | 31 Dec 2022 | $29.8M | -$89.9M | -$86.9M | -$1.33 | -$68.2M | 10-K filed 23 Feb 2023 |
| FY2021 | 31 Dec 2021 | $6.8M | -$89.7M | -$90.9M | -$1.60 | -$52.4M | 10-K filed 24 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $1.6M | -$21.5M | -$0.15 |
| Q1 FY2026 | 31 Mar 2026 | $2.0M | -$19.8M | -$0.15 |
| Q4 FY2025 | 31 Dec 2025 | $1.3M | -$19.8M | -$0.16 |
| Q3 FY2025 | 30 Sep 2025 | $3.3M | -$14.6M | -$0.12 |
| Q2 FY2025 | 30 Jun 2025 | $1.8M | -$15.4M | -$0.13 |
| Q1 FY2025 | 31 Mar 2025 | $1.5M | -$15.1M | -$0.12 |
| Q4 FY2024 | 31 Dec 2024 | $9.2M | -$96.6M | -$1.01 |
| Q3 FY2024 | 30 Sep 2024 | $4.3M | -$7.6M | -$0.11 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Licensing | $6.0M | 76.1% |
| Contract research | $1.9M | 23.9% |
Company events
The newest 8-K filings of 154 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 27 Oct 2026 | 8-K | Results, Investor update, Other events | 2.02, 7.01, 8.01, 9.01 |
| 6 Aug 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 28 Apr 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 11 Mar 2026 | 8-K | Investor update | 7.01 |
| 10 Mar 2026 | 8-K | Investor update | 7.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Jan 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 296 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 6 Aug 2026 | S-3ASR | – |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 4 Jun 2026 | 8-K | 4 Jun 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 28 Apr 2026 | 8-K | 28 Apr 2026 |
| 23 Apr 2026 | ARS | 31 Dec 2025 |
| 23 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 23 Apr 2026 | Leonard Braden Michael, 10% owner | Sale outside a trading plan | 300,000 | $4.53 | $1.4M | 13,950,000 | 27 Apr 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 21 Sep 2026 | Frazier Life Sciences Public Fund, L.P. | 13G | 5.4% | 7.9M |
| 14 Aug 2026 | RA Capital Management, L.P. | 13G amended | 9.1% | 12.7M |
| 12 May 2026 | Vivo Opportunity Fund Holdings, L.P. | 13G amended | 4.3% | 6.0M |
| 27 Apr 2026 | BML Investment Partners, L.P. | 13G amended | 9.9% | 13.9M |
| 7 Apr 2026 | RA Capital Management, L.P. | 13G | 6.3% | 7.6M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Mar 2026 | Deep Track Capital, LP | 13G | 7% | 9.3M |
| 9 Feb 2026 | BML Investment Partners, L.P. | 13G amended | 11.9% | 14.3M |
| 21 Jan 2026 | BlackRock, Inc. | 13G amended | 6.2% | 6.7M |
| 9 Jan 2026 | Biosion, Inc. | 13G amended | 9.4% | 11.3M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 15.0M | -17.39% | 2.95 |
| 30 Sep 2026 | 18.2M | +13.16% | 6.48 |
| 15 Sep 2026 | 16.1M | +5.89% | 6.38 |
| 31 Aug 2026 | 15.2M | +3.2% | 8.67 |
| 14 Aug 2026 | 14.7M | +6.79% | 7.01 |
| 31 Jul 2026 | 13.8M | +3.13% | 8.66 |
| 15 Jul 2026 | 13.4M | +17.12% | 6.92 |
| 30 Jun 2026 | 11.4M | +28.16% | 4.27 |
Funds that hold it
From each fund's latest Form 13F.
162 funds held it at 30 Jun 2026: 94 added and 31 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Ra Capital Management, L.P. | 12,723,026 | $67.3M | +5,918,954 |
| BML Capital Management, LLC | 11,975,000 | $63.3M | -2,275,000 |
| BlackRock, Inc. | 10,037,008 | $53.1M | +2,629,943 |
| Deep Track Capital, LP | 9,345,000 | $49.4M | 0 |
| Vivo Capital, LLC | 6,694,637 | $35.4M | +27,971 |
| Vanguard Capital Management LLC | 5,817,866 | $30.8M | +650,397 |
| Frazier Life Sciences Management, L.P. | 4,925,374 | $26.1M | 0 |
| Rock Springs Capital Management LP | 4,330,532 | $22.9M | -142,118 |
| Adage Capital Partners GP, L.l.c. | 4,071,000 | $21.5M | +200,000 |
| Decheng Capital LLC | 4,041,736 | $21.4M | 0 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B